Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 67

1.

Mice lacking a Myc enhancer that includes human SNP rs6983267 are resistant to intestinal tumors.

Sur IK, Hallikas O, Vähärautio A, Yan J, Turunen M, Enge M, Taipale M, Karhu A, Aaltonen LA, Taipale J.

Science. 2012 Dec 7;338(6112):1360-3. doi: 10.1126/science.1228606. Epub 2012 Nov 1.

2.

Role of c-Myc in intestinal tumorigenesis of the ApcMin/+ mouse.

Ignatenko NA, Holubec H, Besselsen DG, Blohm-Mangone KA, Padilla-Torres JL, Nagle RB, de Alboránç IM, Guillen-R JM, Gerner EW.

Cancer Biol Ther. 2006 Dec;5(12):1658-64. Epub 2006 Dec 7.

PMID:
17106247
3.

Inhibition of intestinal polyposis with reduced angiogenesis in ApcMin/+ mice due to decreases in c-Myc expression.

Yekkala K, Baudino TA.

Mol Cancer Res. 2007 Dec;5(12):1296-303. doi: 10.1158/1541-7786.MCR-07-0232. Erratum in: Mol Cancer Res. 2008 Feb;6(2):340.

4.

An 8q24 gene desert variant associated with prostate cancer risk confers differential in vivo activity to a MYC enhancer.

Wasserman NF, Aneas I, Nobrega MA.

Genome Res. 2010 Sep;20(9):1191-7. doi: 10.1101/gr.105361.110. Epub 2010 Jul 13.

5.

Upregulation of c-MYC in cis through a large chromatin loop linked to a cancer risk-associated single-nucleotide polymorphism in colorectal cancer cells.

Wright JB, Brown SJ, Cole MD.

Mol Cell Biol. 2010 Mar;30(6):1411-20. doi: 10.1128/MCB.01384-09. Epub 2010 Jan 11.

6.

The proprotein convertase PC5/6 is protective against intestinal tumorigenesis: in vivo mouse model.

Sun X, Essalmani R, Seidah NG, Prat A.

Mol Cancer. 2009 Sep 8;8:73. doi: 10.1186/1476-4598-8-73.

7.

Cancer. The utility of mouse models in post-GWAS research.

Lewis A, Tomlinson I.

Science. 2012 Dec 7;338(6112):1301-2. doi: 10.1126/science.1231733. No abstract available.

PMID:
23224545
9.
10.

The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling.

Tuupanen S, Turunen M, Lehtonen R, Hallikas O, Vanharanta S, Kivioja T, Björklund M, Wei G, Yan J, Niittymäki I, Mecklin JP, Järvinen H, Ristimäki A, Di-Bernardo M, East P, Carvajal-Carmona L, Houlston RS, Tomlinson I, Palin K, Ukkonen E, Karhu A, Taipale J, Aaltonen LA.

Nat Genet. 2009 Aug;41(8):885-90. doi: 10.1038/ng.406. Epub 2009 Jun 28.

PMID:
19561604
11.

The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer.

Pomerantz MM, Ahmadiyeh N, Jia L, Herman P, Verzi MP, Doddapaneni H, Beckwith CA, Chan JA, Hills A, Davis M, Yao K, Kehoe SM, Lenz HJ, Haiman CA, Yan C, Henderson BE, Frenkel B, Barretina J, Bass A, Tabernero J, Baselga J, Regan MM, Manak JR, Shivdasani R, Coetzee GA, Freedman ML.

Nat Genet. 2009 Aug;41(8):882-4. doi: 10.1038/ng.403. Epub 2009 Jun 28.

12.
13.

The intestinal nuclear receptor signature with epithelial localization patterns and expression modulation in tumors.

Modica S, Gofflot F, Murzilli S, D'Orazio A, Salvatore L, Pellegrini F, Nicolucci A, Tognoni G, Copetti M, Valanzano R, Veschi S, Mariani-Costantini R, Palasciano G, Schoonjans K, Auwerx J, Moschetta A.

Gastroenterology. 2010 Feb;138(2):636-48, 648.e1-12. doi: 10.1053/j.gastro.2009.09.060. Epub 2009 Oct 8.

PMID:
19818784
14.

Activation of c-MYC and c-MYB proto-oncogenes is associated with decreased apoptosis in tumor colon progression.

Greco C, Alvino S, Buglioni S, Assisi D, Lapenta R, Grassi A, Stigliano V, Mottolese M, Casale V.

Anticancer Res. 2001 Sep-Oct;21(5):3185-92.

PMID:
11848471
15.

Pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity.

Kim J, Roh M, Abdulkadir SA.

BMC Cancer. 2010 Jun 1;10:248. doi: 10.1186/1471-2407-10-248.

16.

Intestinal adenoma formation and MYC activation are regulated by cooperation between MYB and Wnt signaling.

Ciznadija D, Tothill R, Waterman ML, Zhao L, Huynh D, Yu RM, Ernst M, Ishii S, Mantamadiotis T, Gonda TJ, Ramsay RG, Malaterre J.

Cell Death Differ. 2009 Nov;16(11):1530-8. doi: 10.1038/cdd.2009.94. Epub 2009 Jul 17.

17.

Dual functions of E2F-1 in a transgenic mouse model of liver carcinogenesis.

Conner EA, Lemmer ER, Omori M, Wirth PJ, Factor VM, Thorgeirsson SS.

Oncogene. 2000 Oct 19;19(44):5054-62.

18.

A comprehensive strategy to combat colon cancer targeting the adenomatous polyposis coli tumor suppressor gene.

Gerner EW, Ignatenko NA, Lance P, Hurley LH.

Ann N Y Acad Sci. 2005 Nov;1059:97-105. Review.

PMID:
16382048
19.

Synergistic interaction of transforming growth factor alpha and c-myc in mouse mammary and salivary gland tumorigenesis.

Amundadottir LT, Johnson MD, Merlino G, Smith GH, Dickson RB.

Cell Growth Differ. 1995 Jun;6(6):737-48.

20.

Role of nucleotide excision repair deficiency in intestinal tumorigenesis in multiple intestinal neoplasia (Min) mice.

Steffensen IL, Schut HA, Nesland JM, Tanaka K, Alexander J.

Mutat Res. 2006 Dec 10;611(1-2):71-82. Epub 2006 Sep 8.

PMID:
16962818

Supplemental Content

Support Center